Back
Halozyme Therapeutics Stock Price Chart
"EarnPhone": The Investment Hidden in Plain Sight
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Buy
54
HALO
Halozyme Therapeutics
Last Price:
59.25
Seasonality Move:
10.79%
7 Day Trial
ALL ACCESS PASS
$
7
"The Next Apple?" - Mode's Growth Story is Turning Heads
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.- The current trend is moderately bearish and HALO is experiencing slight selling pressure.
Halozyme Therapeutics Price Chart Indicators
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 61.02 | Sell |
| 20-day SMA: | 61.52 | Sell |
| 50-day SMA: | 58.19 | Buy |
| 200-day SMA: | 45.38 | Buy |
| 8-day EMA: | 60.73 | Sell |
| 20-day EMA: | 60.61 | Sell |
| 50-day EMA: | 58.06 | Buy |
| 200-day EMA: | 48.72 | Buy |
Halozyme Therapeutics Technical Analysis Indicators
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 0.61 | Buy |
| Relative Strength Index (14 RSI): | 46.44 | Sell |
| Chaikin Money Flow: | -25929 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | ( - ) | Buy |
| Bollinger Bands (100): | ( - ) | Buy |
Halozyme Therapeutics Technical Analysis
| Sep 9 | Sep 10 | Sep 11 | Sep 12 | Sep 13 | Sep 16 | Sep 17 | Sep 18 | Sep 19 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep | ||||||||||
| 09 | 10 | 11 | 12 | 13 | 16 | 17 | 18 | 19 | 20 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Technical Analysis for Halozyme Therapeutics Stock
Is Halozyme Therapeutics Stock a Buy?
- Halozyme Therapeutics share price is 59.26 while HALO 8-day simple moving average is 61.02, which is a Sell signal.
- The stock price of HALO is 59.26 while Halozyme Therapeutics 20-day SMA is 61.52, which makes it a Sell.
- Halozyme Therapeutics 50-day simple moving average is 58.19 while HALO share price is 59.26, making it a Buy technically.
- HALO stock price is 59.26 and Halozyme Therapeutics 200-day simple moving average is 45.38, creating a Buy signal.
HALO Technical Analysis vs Fundamental Analysis
Buy
54
Halozyme Therapeutics (HALO)
is a Buy
Is Halozyme Therapeutics a Buy or a Sell?
-
Halozyme Therapeutics stock is rated a Buy
The current Halozyme Therapeutics [HALO] share price is $59.26. The Score for HALO is 54, which is 8% above its historic median score of 50, and infers lower risk than normal.
Halozyme Therapeutics Stock Info
Market Cap:
7.51B
Price in USD:
59.26
Share Volume:
1.45M
Halozyme Therapeutics 52-Week Range
52-Week High:
65.53
52-Week Low:
32.83
Buy
54
Halozyme Therapeutics (HALO)
is a Buy
Halozyme Therapeutics Share Price Forecast
-
What is the Halozyme Therapeutics stock price today?
The Halozyme Therapeutics stock price is 59.26 USD today. -
Will HALO stock go up or go down?
Halozyme Therapeutics> share price is forecast to RISE/FALL based on technical indicators -
Is Halozyme Therapeutics overvalued?
According to simple moving average, exponential moving average, oscillators, and other technical indicators, Halozyme Therapeutics is not overvalued.
Is Halozyme Therapeutics Stock a Buy?
- Halozyme Therapeutics share price is 59.26 while HALO 8-day exponential moving average is 60.73, which is a Sell signal.
- The stock price of HALO is 59.26 while Halozyme Therapeutics 20-day EMA is 60.61, which makes it a Sell.
- Halozyme Therapeutics 50-day exponential moving average is 58.06 while HALO share price is 59.26, making it a Buy technically.
- HALO stock price is 59.26 and Halozyme Therapeutics 200-day simple moving average is 48.72, creating a Buy signal.
Fundamental Analysis of Halozyme Therapeutics
Is Halozyme Therapeutics a good investment?
- Analysts estimate an earnings increase this quarter of $0.29 per share, an increase next quarter of $0.20 per share, an increase this year of $1.20 per share, and an increase next year of $0.78 per share.
Technical Analysis of Halozyme Therapeutics
Should I short Halozyme Therapeutics stock?
- HALO Moving Average Covergence Divergence (MACD) indicator is 0.61, suggesting Halozyme Therapeutics is a Buy
- Halozyme Therapeutics Relative Strength Index (RSI) is 46.44, which suggest Halozyme Therapeutics is oversold
- The Bollinger Bands (25) for Halozyme Therapeutics is ( - ), which suggest Halozyme Therapeutics is a Buy
- The Bollinger Bands (100) for Halozyme Therapeutics is ( - ), which suggest Halozyme Therapeutics is a Buy
* Halozyme Therapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.